X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15) 15
female (12) 12
index medicus (12) 12
male (12) 12
adult (10) 10
middle aged (10) 10
chemotherapy (9) 9
oncology (9) 9
cancer (8) 8
hematology, oncology and palliative medicine (8) 8
lymphomas (8) 8
aged (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
aged, 80 and over (6) 6
care and treatment (6) 6
clinical trials (6) 6
non-hodgkins-lymphoma (6) 6
rituximab (6) 6
treatment outcome (6) 6
cyclophosphamide - administration & dosage (5) 5
disease-free survival (5) 5
drug administration schedule (5) 5
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cyclophosphamide (4) 4
doxorubicin - administration & dosage (4) 4
france (4) 4
hematology (4) 4
lymphoma (4) 4
medicine, general & internal (4) 4
neoplasm staging (4) 4
prednisone (4) 4
prednisone - administration & dosage (4) 4
survival (4) 4
survival analysis (4) 4
vincristine (4) 4
abridged index medicus (3) 3
adolescent (3) 3
antibodies, monoclonal, murine-derived - therapeutic use (3) 3
b-cell lymphoma (3) 3
cyclophosphamide - adverse effects (3) 3
doxorubicin (3) 3
doxorubicin - adverse effects (3) 3
internal medicine (3) 3
lymphoma, large b-cell, diffuse - drug therapy (3) 3
neutropenia (3) 3
odds ratio (3) 3
prednisone - adverse effects (3) 3
prognosis (3) 3
prospective studies (3) 3
response criteria (3) 3
salvage therapy (3) 3
side effects (3) 3
survival rate (3) 3
therapy (3) 3
tumors (3) 3
vincristine - administration & dosage (3) 3
young adult (3) 3
adults (2) 2
age (2) 2
aggressive lymphomas (2) 2
antibodies, monoclonal, murine-derived - administration & dosage (2) 2
bone marrow (2) 2
combination (2) 2
cyclophosphamide - therapeutic use (2) 2
cytarabine - administration & dosage (2) 2
dehydrogenases (2) 2
disease progression (2) 2
diseases (2) 2
doxorubicin - therapeutic use (2) 2
drug therapy (2) 2
elderly-patients (2) 2
epidemiology (2) 2
follow-up studies (2) 2
further section · weitere sektionen (2) 2
hemic and lymphatic diseases (2) 2
immunologic factors - therapeutic use (2) 2
lenalidomide (2) 2
leukemia (2) 2
low-grade (2) 2
lymphoma, follicular - drug therapy (2) 2
lymphoma, large b-cell, diffuse - mortality (2) 2
lymphoma, large b-cell, diffuse - pathology (2) 2
lymphoma, non-hodgkin - drug therapy (2) 2
lymphoma, non-hodgkin - mortality (2) 2
lymphoma, t-cell, peripheral - drug therapy (2) 2
malignant-lymphoma (2) 2
management (2) 2
medical prognosis (2) 2
medicine & public health (2) 2
motivation (2) 2
multiple-myeloma (2) 2
neoplasms - drug therapy (2) 2
non-hodgkin's lymphomas (2) 2
oncology, experimental (2) 2
patients (2) 2
plus rituximab (2) 2
prednisone - therapeutic use (2) 2
product development (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 8, pp. 773 - 784
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. e555 - e567
Summary Double-hit lymphoma (DHL) is a subgroup of aggressive lymphomas with both MYC and BCL2 gene rearrangements, characterised by a rapidly progressing... 
Hematology, Oncology and Palliative Medicine | Proteins | Lymphomas
Journal Article
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2017, Volume 4, Issue 1, pp. e46 - e55
Journal Article